tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ABBV Stock Latest News

AbbVie’s HIV Treatment Study Update: Key Insights for Investors
Company AnnouncementsAbbVie’s HIV Treatment Study Update: Key Insights for Investors
7h ago
ABBV
AbbVie reports results from Phase 3 studies evaluating upadacitinib
PremiumThe Fly
AbbVie reports results from Phase 3 studies evaluating upadacitinib
11h ago
ABBV
ABBV Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ABBV Earnings this Week: How Will it Perform?
14h ago
ABBV
AbbVie’s Latest Study on JUVÉDERM: What Investors Need to Know
PremiumCompany Announcements
AbbVie’s Latest Study on JUVÉDERM: What Investors Need to Know
2d ago
ABBV
AbbVie’s Mass Balance Study of ABBV-1354: Key Insights for Investors
PremiumCompany Announcements
AbbVie’s Mass Balance Study of ABBV-1354: Key Insights for Investors
2d ago
ABBV
AbbVie Advances with Emraclidine Study in Elderly: A Potential Game Changer?
PremiumCompany AnnouncementsAbbVie Advances with Emraclidine Study in Elderly: A Potential Game Changer?
2d ago
ABBV
AbbVie’s New Study on ELAPR002f Gel: A Potential Game-Changer for Acne Scars
Premium
Company Announcements
AbbVie’s New Study on ELAPR002f Gel: A Potential Game-Changer for Acne Scars
2d ago
ABBV
AbbVie’s New Phase 2 Study Targets MET Amplification in Solid Tumors
Premium
Company Announcements
AbbVie’s New Phase 2 Study Targets MET Amplification in Solid Tumors
2d ago
ABBV
AbbVie’s Promising Study on ABBV-6628 for Geographic Atrophy: What Investors Need to Know
PremiumCompany Announcements
AbbVie’s Promising Study on ABBV-6628 for Geographic Atrophy: What Investors Need to Know
2d ago
ABBV
AbbVie’s Cariprazine Study: A New Chapter in Pediatric Treatment
PremiumCompany Announcements
AbbVie’s Cariprazine Study: A New Chapter in Pediatric Treatment
2d ago
ABBV
AbbVie’s ABBV-303 Study Terminated: Implications for Investors
PremiumCompany Announcements
AbbVie’s ABBV-303 Study Terminated: Implications for Investors
2d ago
ABBV
AbbVie’s Fosigotifator Study Termination: Impact on MDD Treatment Pipeline
PremiumCompany Announcements
AbbVie’s Fosigotifator Study Termination: Impact on MDD Treatment Pipeline
2d ago
ABBV
AbbVie Withdraws Study on Hair Loss in Oriahnn Users: Market Implications
PremiumCompany AnnouncementsAbbVie Withdraws Study on Hair Loss in Oriahnn Users: Market Implications
2d ago
ABBV
AbbVie’s AML Study Termination: Implications for Investors
Premium
Company Announcements
AbbVie’s AML Study Termination: Implications for Investors
2d ago
ABBV
AbbVie’s Elagolix Pregnancy Study Terminated: Market Implications
Premium
Company Announcements
AbbVie’s Elagolix Pregnancy Study Terminated: Market Implications
2d ago
ABBV
Options Volatility and Implied Earnings Moves This Week, October 28 – October 31, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, October 28 – October 31, 2025
2d ago
V
BA
Avidity Biosciences downgraded to Neutral from Buy at Roth Capital
PremiumThe Fly
Avidity Biosciences downgraded to Neutral from Buy at Roth Capital
2d ago
LLY
MRK
AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment?
PremiumCompany Announcements
AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment?
5d ago
ABBV
AbbVie’s Upadacitinib Study Completes: Promising Results for Atopic Dermatitis
PremiumCompany Announcements
AbbVie’s Upadacitinib Study Completes: Promising Results for Atopic Dermatitis
5d ago
ABBV
AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges
PremiumRatingsAbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges
5d ago
ABBV
AbbVie’s Atogepant Study: A Step Forward in Migraine Prevention
Premium
Company Announcements
AbbVie’s Atogepant Study: A Step Forward in Migraine Prevention
8d ago
ABBV
AbbVie reports ‘positive’ results from Phase 3b/4 SELECT-SWITCH study
Premium
The Fly
AbbVie reports ‘positive’ results from Phase 3b/4 SELECT-SWITCH study
9d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >